Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Angiosarcoma is a rare and aggressive vascular cancer with poor survival rates.
• Limited understanding of angiosarcoma's molecular pathology hinders effective treatment development.
• Developing relevant animal models is crucial for studying angiosarcoma tumorigenesis and therapeutic strategies.

Purpose of the Study:

• To create a genetically engineered mouse model that recapitulates human angiosarcoma.
• To investigate the efficacy of targeted therapies, specifically mTOR and MEK inhibitors, in this model.
• To identify effective combination therapies for angiosarcoma.

Main Methods:

• Generated a mouse model by conditionally deleting Trp53, Pten, and Ptpn12 in endothelial cells.
• Analyzed tumor histology and molecular signaling pathways (PI3K/mTOR, MAPK).
• Treated tumor-bearing mice with single-agent and combination mTOR and MEK inhibitors.

Main Results:

• The mouse model exhibited angiosarcoma histology and molecular features similar to human disease.
• Single-agent mTOR or MEK inhibitors caused transient tumor regression.
• Combined mTOR and MEK inhibition led to sustained and profound tumor regression.

Conclusions:

• The developed mouse model accurately reflects human angiosarcoma, aiding in understanding its pathology.
• Targeting PI3K/mTOR and MAPK pathways is a viable strategy for angiosarcoma treatment.
• Combination therapy with mTOR and MEK inhibitors shows significant therapeutic potential for angiosarcoma.